Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Endocrine |
| Therapuetic Areas: | Endocrinology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/17/2019 |
| Start Date: | August 21, 2018 |
| End Date: | August 2022 |
| Contact: | Ravinder Grewal, MD |
| Email: | grewalr@mskcc.org |
| Phone: | 212-639-2872 |
The purpose of this study is to evaluate a new diagnostic imaging test, positron emission
tomography (PET), with a different radioactive form of iodine called iodine-124. This form is
able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new
test determines sufficient radioiodine uptake in the cancer, treatment will continue as
usual. However, if the new test shows only low radioiodine uptake, a decision may be made
that the benefit from radioiodine therapy is insufficient and that another form of therapy is
preferred.
tomography (PET), with a different radioactive form of iodine called iodine-124. This form is
able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new
test determines sufficient radioiodine uptake in the cancer, treatment will continue as
usual. However, if the new test shows only low radioiodine uptake, a decision may be made
that the benefit from radioiodine therapy is insufficient and that another form of therapy is
preferred.
Inclusion Criteria:
- Adult thyroid carcinoma patients who have had a total thyroidectomy, histology
confirmed by pathology.
- Adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic
disease, or are under a protocol intended to explore re-induction therapy for 131I
uptake, and are about to undergo Thyrogen-assisted dosimetry at MSKCC.
- The patient and physician are planning to administer 131I for therapy if persistent
radioiodine-avid metastases are present.
- All subjects must have measurable disease, documented within the previous six months
by ultrasonography (US), MRI, FDG PET/CT, or non-contrast CT scanning.
Exclusion Criteria:
- Age less than 18 years.
- Patients who are pregnant.
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Ravinder Grewal, MD
Phone: 212-639-2872
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
